PMID- 31840311 OWN - NLM STAT- MEDLINE DCOM- 20201007 LR - 20201007 IS - 1600-0609 (Electronic) IS - 0902-4441 (Linking) VI - 104 IP - 3 DP - 2020 Mar TI - Use of eltrombopag for patients 65 years old or older with immune thrombocytopenia. PG - 259-270 LID - 10.1111/ejh.13370 [doi] AB - BACKGROUND: Eltrombopag is useful for immune thrombocytopenia (ITP). However, results of clinical trials may not accurately mirror clinical practice reality. Here we evaluated eltrombopag for primary and secondary ITP in our >/=65-year-old population. METHODS: A total of 106 primary ITP patients (16 with newly diagnosed ITP, 16 with persistent ITP, and 74 with chronic ITP) and 39 secondary ITP patients (20 with ITP secondary to immune disorders, 7 with ITP secondary to infectious diseases, and 12 with ITP secondary to lymphoproliferative disorders [LPD]) were retrospectively evaluated. RESULTS: Median age of our cohort was 76 (interquartile range, IQR, 70-81) years. 75.9% of patients yielded a platelet response including 66.2% complete responders. Median time to platelet response was 14 (IQR, 8-21) days. Median time on response was 320 (IQR, 147-526) days. Sixty-three adverse events (AEs), mainly grade 1-2, occurred. The most common were hepatobiliary laboratory abnormalities (HBLAs) and headaches. One transient ischemic attack in a newly diagnosed ITP and two self-limited pulmonary embolisms in secondary ITP were the only thrombotic events observed. CONCLUSION: Eltrombopag showed efficacy and safety in ITP patients aged >/=65 years with primary and secondary ITP. However, efficacy results in LPD-ITP were poor. A relatively high number of deaths were observed. CI - (c) 2019 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd. FAU - Gonzalez-Lopez, Tomas Jose AU - Gonzalez-Lopez TJ AUID- ORCID: 0000-0001-9575-1816 AD - Department of Hematology, Hospital Universitario de Burgos, Burgos, Spain. AD - Department of Health Sciences, University of Burgos, Burgos, Spain. FAU - Sanchez-Gonzalez, Blanca AU - Sanchez-Gonzalez B AD - Department of Hematology, Hospital del Mar, Barcelona, Spain. FAU - Jarque, Isidro AU - Jarque I AD - Department of Hematology, Hospital Universitario La Fe, Valencia, Spain. FAU - Bernat, Silvia AU - Bernat S AD - Department of Hematology, Hospital de La Plana, Castellon, Spain. FAU - Fernandez-Fuertes, Fernando AU - Fernandez-Fuertes F AD - Department of Hematology, Hospital Universitario Insular de Gran Canaria, Las Palmas de Gran Canaria, Spain. FAU - Caparros, Isabel AU - Caparros I AD - Department of Hematology, Hospital Clinico de Malaga, Malaga, Spain. FAU - Soto, Inmaculada AU - Soto I AD - Department of Hematology, Hospital Universitario Central de Asturias, Oviedo (Asturias), Spain. FAU - Fernandez-Rodriguez, Angeles AU - Fernandez-Rodriguez A AD - Department of Hematology, Hospital Universitario Central de Asturias, Oviedo (Asturias), Spain. FAU - Bolanos, Estefania AU - Bolanos E AD - Department of Hematology, Hospital Universitario Clinico San Carlos, Madrid, Spain. FAU - Perez-Rus, Gloria AU - Perez-Rus G AD - Department of Hematology, Hospital General Universitario Gregorio Maranon, Madrid, Spain. FAU - Pascual, Cristina AU - Pascual C AD - Department of Hematology, Hospital General Universitario Gregorio Maranon, Madrid, Spain. FAU - Hernandez-Rivas, Jose Angel AU - Hernandez-Rivas JA AD - Department of Hematology, Hospital Infanta Leonor, Madrid, Spain. FAU - Lopez-Ansoar, Elsa AU - Lopez-Ansoar E AD - Department of Hematology, Complejo Hospitalario Universitario de Orense, Orense, Spain. FAU - Gomez-Nunez, Marta AU - Gomez-Nunez M AD - Department of Hematology, Hospital Parc Tauli, Sabadell (Barcelona), Spain. FAU - Martinez-Robles, Violeta AU - Martinez-Robles V AD - Department of Hematology, Hospital de Leon, Leon, Spain. FAU - Olivera, Pavel AU - Olivera P AD - Department of Hematology, Hospital Universitario Vall de Hebron, Barcelona, Spain. FAU - Yera Cobo, Maria AU - Yera Cobo M AD - Department of Hematology, Hospital Puerta del Mar, Cadiz, Spain. FAU - Penarrubia, Maria Jesus AU - Penarrubia MJ AD - Department of Hematology, Hospital Clinico de Valladolid, Valladolid, Spain. FAU - Fernandez-Minano, Carmen AU - Fernandez-Minano C AD - Department of Hematology, Hospital Vega Baja, Orihuela (Alicante), Spain. FAU - de Cabo, Erik AU - de Cabo E AD - Department of Hematology, Hospital del Bierzo, Ponferrada (Leon), Spain. FAU - Martinez Badas, Maria Paz AU - Martinez Badas MP AD - Department of Hematology, Hospital de Avila, Avila, Spain. FAU - Perdomo, German AU - Perdomo G AD - Department of Health Sciences, University of Burgos, Burgos, Spain. FAU - Garcia-Frade, Luis Javier AU - Garcia-Frade LJ AD - Department of Hematology, Hospital Universitario Rio Hortega, Valladolid, Spain. LA - eng PT - Journal Article DEP - 20200203 PL - England TA - Eur J Haematol JT - European journal of haematology JID - 8703985 RN - 0 (Benzoates) RN - 0 (Biomarkers) RN - 0 (Hydrazines) RN - 0 (Pyrazoles) RN - S56D65XJ9G (eltrombopag) SB - IM MH - Age Factors MH - Aged MH - Aged, 80 and over MH - Benzoates/administration & dosage/adverse effects/*therapeutic use MH - Biomarkers MH - Combined Modality Therapy MH - Comorbidity MH - Drug Therapy, Combination MH - Female MH - Humans MH - Hydrazines/administration & dosage/adverse effects/*therapeutic use MH - Male MH - Prognosis MH - Purpura, Thrombocytopenic, Idiopathic/blood/diagnosis/*drug therapy MH - Pyrazoles/administration & dosage/adverse effects/*therapeutic use MH - Retrospective Studies MH - Treatment Outcome OTO - NOTNLM OT - elderly OT - eltrombopag OT - immune thrombocytopenia OT - primary OT - secondary EDAT- 2019/12/17 06:00 MHDA- 2020/10/08 06:00 CRDT- 2019/12/17 06:00 PHST- 2019/10/08 00:00 [received] PHST- 2019/12/03 00:00 [revised] PHST- 2019/12/11 00:00 [accepted] PHST- 2019/12/17 06:00 [pubmed] PHST- 2020/10/08 06:00 [medline] PHST- 2019/12/17 06:00 [entrez] AID - 10.1111/ejh.13370 [doi] PST - ppublish SO - Eur J Haematol. 2020 Mar;104(3):259-270. doi: 10.1111/ejh.13370. Epub 2020 Feb 3.